Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.45 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3107244 | 0.86 | PPARD (0.44) | EPHX2NR1H4DDR1GCGRLMNA | |
| SCHEMBL3878993 | 0.86 | TRPV1 (0.49) | TRPV1EPHX2NR1H4DDR1GCGR | |
| SCHEMBL3116597 | 0.83 | KCNK2 (0.40) | TRPV1EPHX2NR1H4DDR1GCGR | |
| SCHEMBL3113188 | 0.81 | PPARD (0.44) | EPHX2NR1H4DDR1GCGRLMNA | |
| SCHEMBL3944534 | 0.80 | TRPV1 (0.44) | TRPV1EPHX2NR1H4DDR1GCGR | |
| SCHEMBL3110196 | 0.79 | DPP4 (0.48) | EPHX2NR1H4DDR1GCGRLMNA | |
| SCHEMBL3113355 | 0.79 | PPARD (0.47) | EPHX2NR1H4PPARALMNAMAPK1 | |
| SCHEMBL4912775 | 0.79 | CNR1 (0.46) | — | |
| SCHEMBL3113229 | 0.78 | CNR1 (0.55) | MAPK1 | |
| SCHEMBL4914279 | 0.78 | CNR1 (0.43) | GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021070-A1 | PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2008-01-24 | — | — | US | claimed |
| EP-1805143-A1 | PYRIDINE DERIVATIVES AND THE PREPARATION AND THE THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-07-11 | — | — | EP | claimed |
| WO-2006042955-A1 | PYRIDINE DERIVATIVES AND THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2006-04-27 | — | — | WO | claimed |
| US-20080021070-A1 | PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021070-A1 | PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | CNR1, CNR2, GPR18 | TRPV1 17/4885EPHX2 415/4885NR1H4 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.